- Home
- AUST vs AFMD Comparison
AUST vs AFMD Comparison
Compare AUST & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- AFMD
- Stock Information
- Founded
- AUST 2020
- AFMD 2000
- Country
- AUST Canada
- AFMD Germany
- Employees
- AUST N/A
- AFMD N/A
- Industry
- AUST
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- AFMD Health Care
- Exchange
- AUST Nasdaq
- AFMD Nasdaq
- Market Cap
- AUST 15.5M
- AFMD 17.5M
- IPO Year
- AUST 2022
- AFMD 2014
- Fundamental
- Price
- AUST $1.25
- AFMD $1.10
- Analyst Decision
- AUST
- AFMD Strong Buy
- Analyst Count
- AUST 0
- AFMD 5
- Target Price
- AUST N/A
- AFMD $13.50
- AVG Volume (30 Days)
- AUST 92.5K
- AFMD 300.1K
- Earning Date
- AUST 03-03-2025
- AFMD 11-14-2024
- Dividend Yield
- AUST N/A
- AFMD N/A
- EPS Growth
- AUST N/A
- AFMD N/A
- EPS
- AUST N/A
- AFMD N/A
- Revenue
- AUST N/A
- AFMD $6,287,085.00
- Revenue This Year
- AUST N/A
- AFMD N/A
- Revenue Next Year
- AUST N/A
- AFMD $212.48
- P/E Ratio
- AUST N/A
- AFMD N/A
- Revenue Growth
- AUST N/A
- AFMD N/A
- 52 Week Low
- AUST $0.62
- AFMD $1.03
- 52 Week High
- AUST $3.19
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- AUST 46.23
- AFMD 26.91
- Support Level
- AUST $1.05
- AFMD $1.03
- Resistance Level
- AUST $1.27
- AFMD $1.19
- Average True Range (ATR)
- AUST 0.10
- AFMD 0.11
- MACD
- AUST 0.03
- AFMD 0.05
- Stochastic Oscillator
- AUST 64.82
- AFMD 13.73
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.